The pharmaceutical industry is under extreme pressure to address major challenges such as eliminating drug candidates at an earlier and less costly stage of development, reducing time to market and R & D costs.

With approximately 90% of clinical candidates failing at the development stage at a cost of $50 - $70 million each, pharmaceutical companies have for some time adopted the “fail early, fail cheaply” approach to reduce costs, but many pharmaceutical companies & professionals are realising that promising candidates are being eliminated due to the selection criteria applied in the profiling process. Pharmaceutical companies are therefore missing out on possible blockbuster opportunities as early failures are rarely if ever revisited.

The preclinical stage of development experiences the highest attrition rates with only 0.1% of molecules screened in drug discovery entering phase I, therefore pharmaceutical companies are under extreme pressure to improve the preclinical stages of drug development.

Preclinical World has been commissioned to address the most challenging issues in the early stage and preclinical pharmaceutical industry; it will explore solution providers, innovation, trends, strategies, services, licensing agreements, financing and legislation to create a one-stop shop for time sensitive pharmaceutical decision makers. Preclinical World will bring together carefully selected solution providers who have been researched and identified as possessing the solutions to address today's most strategic challenges.

Preclinical World is in constant touch with all of the major pharmaceutical company’s as-well-as small and start-up Pharma and biotech companies to provide them with the platform to communicate with solution providers and benchmark with their peers making this a must for any decision makers within the preclinical community.

Some of our readers have been pre qualified as having £1m budgetary spend.

VPs, Directors, Heads of:

R&D Discovery and Development Preclinical Development Screening Research Pharmaceutical Development Science Chief Scientific Officer Toxicology Product Development Safety Technology Chemistry Genetics Analytical

HR Directors / HR Professionals Purchasing Directors MD CEO IT Director Licensing Regulatory Affairs VP Marketing Head Global Marketing Marketing Director Senior Product Managers Commercial Intelligence Managers Marketing Effectiveness Managers Sales & Marketing Director Brand Manager/Director

Recipients include top level decision makers from companies such as:

Abbott Laboratories Akzo Nobel NV Amgen Inc. AstraZeneca Plc. Astellas Pharma Inc. Bayer Group Biogen, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Co. Celltech Group Chiron Elan Corp. Eli Lilly and Co. Genentech Inc. Genzyme General Gilead Sciences

GlaxoSmithKline Plc. Immunex Johnson & Johnson MedImmune Merck & Co. Novartis Novo Nordisk AS Pfizer Inc. Roche Sankyo Co. Sanofi Aventis Schering AG Schering-Plough Corp. Serono International Takeda Chemical Industries Ltd. Wyeth

Copies of Preclinical World are distributed in both print and electronic format.

Authors who have been invited to contribute to Preclinical World include:

• Martina Kaufmann, Biomarker Program Leader, Herceptin. F. Hoffmann-La Roche
• Paul Whiting, Head of Biomarkers and Translational Biology, Discovery Biology Pfizer
• Duncan McHale, Director and European Head of clinical Pharmacogenomics Pfizer
• Harsukh Parmer, Director, Global Discovery Medicine, AstraZeneca
• Hans Guenter Schaefer, Director, Clinical PK/PD Boehringer Ingelheim
• Hugh Salter, Associate Director, Pharmacogenomics AstraZeneca
• Alain Van Gool, Director Genomics & Proteomics, Chair Biomarker Platform, Organon
• Prof. Dr. Eva-Maria Muchitsch, Director, Pharmacology, Toxicology, Preclinicals, Global Preclinical R&D Baxter AG
• Lorenz Mayr, Executive Director Novartis Pharmaceutical
• Stephen Rees, Director, Screening Compond Profiling GSK
• Ian Ragan, Executive Consultant European Scientific Affairs Eli Lily
• Debbie Hartman, Vice President Lead Generation AstraZeneca
• Victor Lobanov, Director Informatics Johnson & Johnson
• Nicolau Beckmann, Head of MRI Laboratory, Novartis
• Ulf Boemer, Head of Technology Development & HTS Infrastructure, Bayer Schering

• Preclinical CRO's
• ADME/Tox [in vivo/in vitro]
• RNA-I
• HTS [High throughput screening]
• Proteomics
• Genomics
• IP
• Raw materials & fine ingredients [API's]
• Lab automation
• Bioinformatics
• Discovery & development
• Combination therapy
• Preclinical Imaging
• Biomarkers

Preclinical World is designed to provide advertisers with qualified responses from new customers through the following mechanisms:

READER REPLY CARD SERVICE

Each copy of Preclinical World contains a reply card, which readers can fill out to receive more information on advertisers. As part of our service, for a period of 12 months following publication we will:

• Transmit all reader responses to you by fax or email within 24 hours of receiving them, so that you can contact your new potential customers without delay.
• Monitor all responses to ensure you receive only genuine qualified enquiries.
• Send you a summary report of all the responses you have received every quarter so that you can assess the quantity and quality of new business your advertisement has generated.

The Internet has become the most important tool for finding information quickly. It is therefore essential that your company achieves high search engine rankings because only the first few results returned by a search engine are ever actually visited. To enable your company to achieve the best possible rankings on GOOGLE – the world’s number one search engine – we will work with you to create a 600 word Profile, optimised for the search engines, which will appear on the official Preclinical World  website.

All search engine studies have shown that the single most important and reliable method to improve the ranking of your own website is to have links into your site from relevant, highly ranked sites, such as the Preclinical World website. Search engine algorithms identify these links, assessing their importance and will reflect this in the subsequent ranking of your website.

To further ensure that you get the maximum amount of targeted traffic to your company’s own website we will: -

• Identify the best combination of keywords for your business and create the relevant <title> and other meta tags based on our research.
• Edit the text of your Profile to ensure the correct balance of keywords for optimal search engine visibility.
• As a high-ranking site, GOOGLE regularly visits the Preclinical World website, thus maintaining your highly ranked presence on their search engine.

Aside from driving more targeted traffic to your website, achieving high search engine rankings provides an extremely powerful and cost-effective method of building brand awareness.

85% of all Internet searches are conducted through GOOGLE.